Stephen Hansen

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | Product DevelopmentScholar Rock shows 55% lean mass preservation for apitegromab vs. Zepbound in Phase II readout By Stephen Hansen, Director of Biopharma IntelligenceTwo recent Phase II studies have established proof of concept that myostatin inhibitors can substantially improve the quality of weight loss, without adding any notable toxicity, when combined with marketed obesity therapies. They also set the bar for the upcoming readout of Lilly’s activin antagonist bimagrumab.

1 week ago | jdsupra.com | Stephen Hansen |William C. Martucci

Although the Massachusetts Noncompetition Agreement Act expressly excludes nonsolicitation agreements from its definition of “noncompetition agreements,” the Massachusetts Supreme Judicial Court (SJC) recently responded to a reported question asking if that exclusion applies when coupling a nonsolicitation agreement with a forfeiture clause triggered by nonsolicitation violations. In a win for the employer in Miele v.

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | DealsVerve takeout adds base editing platform with big CV market opportunities  By Stephen Hansen, Director of Biopharma Intelligence and Lauren Martz, Executive Director of Biopharma IntelligenceLilly is using its obesity cash pile to increase the optionality for its fledgling cardiovascular pipeline through a deal that gives the pharma full control of a clinical-stage modality that it already had rights to in what is expected to be a highly competitive space.

1 week ago | biocentury.com | Stephen Hansen

ARTICLE | DealsVerve takeout adds base editing platform with big CV market opportunities  By Stephen Hansen, Director of Biopharma Intelligence and Lauren Martz, Executive Director of Biopharma IntelligenceLilly is using its obesity cash pile to increase the optionality for its fledgling cardiovascular pipeline through a deal that gives the pharma full control of a clinical-stage modality that it already had rights to in what is expected to be a highly competitive space.

1 week ago | biocentury.com | Stephen Hansen

PODCAST | Product DevelopmentWhat the second death of a DMD patient treated with Elevidys means for gene therapy. Amylin’s momentum grows in obesity, and new leadership’s vision for FDA By Stephen Hansen, Director of Biopharma IntelligenceThe tragic death of a second non-ambulatory DMD patient treated with Elevidys gene therapy from Sarepta Therapeutics Inc.